Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

CMV: early-phase trial registry

3 of 8 indexed CMV trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 3 currently recruiting · #2,176 of 28,707 conditions by registered trial count

CMV: 8 US clinical trials tracked, 3 recruiting.

CMV is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Meridian Bioscience, running 1 of these trials.

Enrollment posture brief

Registry condition cmv

OPEN 3 | RECR 38% | LATE 1 | EARLY 4 | RANK #2176 | SPON 1

Nearest open-share peer: Acute-graft-versus-host Disease (38% recruiting · 8 trials)

Activity, Motor75%Achalasia50%CMV (this)38%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near CMV

CMV lists 3 open slots (38% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for CMV on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. CMV is recruiting below its size-band peers.

    3 of 8 indexed trials (37.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of CMV trials is spread across many organizations.

    Meridian Bioscience accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most CMV trials plan to enrol fewer than 100 people.

    Median target enrolment is 60 among the 8 trials that report a genuine target (sentinel values excluded). 5 of those (62.5%) plan for fewer than 100 participants.

  4. CMV splits between interventional and observational designs.

    5 interventional and 3 observational studies make up this index (62.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 31

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on CMV records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

illumigene CMV assay, illumipro-10 Device
1 trials
Cytotoxic T lymphocytes (CTLs). Drug
1 trials
CMV T cell Immunity Assay Other
1 trials
Historical/Control Other
1 trials
Letermovir 480 mg once daily Drug
1 trials
Simple Syrup Drug
1 trials
Cytogam Drug
1 trials
Valganciclovir Drug
1 trials

US sites by state

Facility locations filed on CMV trials. A trial with sites in several states counts in each.

California 3 trials
Ohio 2 trials
New York 2 trials
Missouri 2 trials
Minnesota 2 trials
Massachusetts 2 trials
Illinois 2 trials
Georgia 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this CMV page

8 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This CMV condition card totals 8 registered trials; most-linked intervention illumigene CMV assay, illumipro-10; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.